vs
OFG BANCORP（OFG）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
OFG BANCORP的季度营收约是Vericel Corp的2.0倍（$184.3M vs $92.9M），OFG BANCORP净利率更高（30.3% vs 25.0%，领先5.3%），Vericel Corp同比增速更快（23.3% vs 0.9%），OFG BANCORP自由现金流更多（$199.3M vs $12.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 2.8%）
OFG Bancorp成立于1964年，总部位于波多黎各圣胡安，是东方银行的金融控股公司。公司通过东方银行、东方金融服务有限责任公司、东方保险有限责任公司等核心子公司，主要面向波多黎各和美属维尔京群岛市场，提供多元化的零售与商业银行、贷款、财富管理相关产品、服务及技术解决方案。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
OFG vs VCEL — 直观对比
营收规模更大
OFG
是对方的2.0倍
$92.9M
营收增速更快
VCEL
高出22.4%
0.9%
净利率更高
OFG
高出5.3%
25.0%
自由现金流更多
OFG
多$186.5M
$12.8M
两年增速更快
VCEL
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $184.3M | $92.9M |
| 净利润 | $55.9M | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 25.7% | 24.1% |
| 净利率 | 30.3% | 25.0% |
| 营收同比 | 0.9% | 23.3% |
| 净利润同比 | 11.0% | 17.3% |
| 每股收益（稀释后） | $1.27 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFGVCEL
| Q4 25 | $184.3M | $92.9M | ||
| Q3 25 | $186.2M | $67.5M | ||
| Q2 25 | $182.4M | $63.2M | ||
| Q1 25 | $178.6M | $52.6M | ||
| Q4 24 | $182.7M | $75.4M | ||
| Q3 24 | $174.7M | $57.9M | ||
| Q2 24 | $179.8M | $52.7M | ||
| Q1 24 | $174.4M | $51.3M |
净利润OFGVCEL
| Q4 25 | $55.9M | $23.2M | ||
| Q3 25 | $51.8M | $5.1M | ||
| Q2 25 | $51.8M | $-553.0K | ||
| Q1 25 | $45.6M | $-11.2M | ||
| Q4 24 | $50.3M | $19.8M | ||
| Q3 24 | $47.0M | $-901.0K | ||
| Q2 24 | $51.1M | $-4.7M | ||
| Q1 24 | $49.7M | $-3.9M |
毛利率OFGVCEL
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
营业利润率OFGVCEL
| Q4 25 | 25.7% | 24.1% | ||
| Q3 25 | 33.0% | 5.1% | ||
| Q2 25 | 36.1% | -3.2% | ||
| Q1 25 | 33.3% | -24.3% | ||
| Q4 24 | 28.9% | 24.5% | ||
| Q3 24 | 35.4% | -4.3% | ||
| Q2 24 | 39.6% | -11.5% | ||
| Q1 24 | 38.9% | -10.7% |
净利率OFGVCEL
| Q4 25 | 30.3% | 25.0% | ||
| Q3 25 | 27.8% | 7.5% | ||
| Q2 25 | 28.4% | -0.9% | ||
| Q1 25 | 25.5% | -21.4% | ||
| Q4 24 | 27.6% | 26.3% | ||
| Q3 24 | 26.9% | -1.6% | ||
| Q2 24 | 28.4% | -8.9% | ||
| Q1 24 | 28.5% | -7.5% |
每股收益（稀释后）OFGVCEL
| Q4 25 | $1.27 | $0.46 | ||
| Q3 25 | $1.16 | $0.10 | ||
| Q2 25 | $1.15 | $-0.01 | ||
| Q1 25 | $1.00 | $-0.23 | ||
| Q4 24 | $1.10 | $0.40 | ||
| Q3 24 | $1.00 | $-0.02 | ||
| Q2 24 | $1.08 | $-0.10 | ||
| Q1 24 | $1.05 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $354.6M |
| 总资产 | $12.5B | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFGVCEL
| Q4 25 | $1.0B | $137.5M | ||
| Q3 25 | $740.3M | $135.4M | ||
| Q2 25 | $851.8M | $116.9M | ||
| Q1 25 | $710.6M | $112.9M | ||
| Q4 24 | $591.1M | $116.2M | ||
| Q3 24 | $680.6M | $101.7M | ||
| Q2 24 | $740.4M | $102.5M | ||
| Q1 24 | $754.4M | $110.6M |
股东权益OFGVCEL
| Q4 25 | $1.4B | $354.6M | ||
| Q3 25 | $1.4B | $321.9M | ||
| Q2 25 | $1.3B | $306.8M | ||
| Q1 25 | $1.3B | $295.5M | ||
| Q4 24 | $1.3B | $292.0M | ||
| Q3 24 | $1.3B | $257.5M | ||
| Q2 24 | $1.2B | $243.0M | ||
| Q1 24 | $1.2B | $233.9M |
总资产OFGVCEL
| Q4 25 | $12.5B | $488.0M | ||
| Q3 25 | $12.2B | $453.3M | ||
| Q2 25 | $12.2B | $435.6M | ||
| Q1 25 | $11.7B | $424.6M | ||
| Q4 24 | $11.5B | $432.7M | ||
| Q3 24 | $11.5B | $390.4M | ||
| Q2 24 | $11.3B | $376.8M | ||
| Q1 24 | $11.2B | $356.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $217.7M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $199.3M | $12.8M |
| 自由现金流率自由现金流/营收 | 108.1% | 13.8% |
| 资本支出强度资本支出/营收 | 10.0% | 2.4% |
| 现金转化率经营现金流/净利润 | 3.90× | 0.65× |
| 过去12个月自由现金流最近4个季度 | $345.4M | $24.7M |
8季度趋势，按日历期对齐
经营现金流OFGVCEL
| Q4 25 | $217.7M | $15.0M | ||
| Q3 25 | $39.5M | $22.1M | ||
| Q2 25 | $35.9M | $8.2M | ||
| Q1 25 | $83.1M | $6.6M | ||
| Q4 24 | $252.5M | $22.2M | ||
| Q3 24 | $58.1M | $10.2M | ||
| Q2 24 | $95.1M | $18.5M | ||
| Q1 24 | $61.0M | $7.2M |
自由现金流OFGVCEL
| Q4 25 | $199.3M | $12.8M | ||
| Q3 25 | $35.5M | $19.5M | ||
| Q2 25 | $31.8M | $81.0K | ||
| Q1 25 | $78.7M | $-7.6M | ||
| Q4 24 | $231.2M | $8.5M | ||
| Q3 24 | $51.8M | $-9.2M | ||
| Q2 24 | $90.4M | $1.8M | ||
| Q1 24 | $54.8M | $-6.8M |
自由现金流率OFGVCEL
| Q4 25 | 108.1% | 13.8% | ||
| Q3 25 | 19.1% | 28.8% | ||
| Q2 25 | 17.4% | 0.1% | ||
| Q1 25 | 44.1% | -14.5% | ||
| Q4 24 | 126.5% | 11.2% | ||
| Q3 24 | 29.6% | -15.9% | ||
| Q2 24 | 50.3% | 3.4% | ||
| Q1 24 | 31.4% | -13.3% |
资本支出强度OFGVCEL
| Q4 25 | 10.0% | 2.4% | ||
| Q3 25 | 2.1% | 3.9% | ||
| Q2 25 | 2.3% | 12.9% | ||
| Q1 25 | 2.4% | 27.0% | ||
| Q4 24 | 11.7% | 18.3% | ||
| Q3 24 | 3.6% | 33.5% | ||
| Q2 24 | 2.6% | 31.8% | ||
| Q1 24 | 3.5% | 27.3% |
现金转化率OFGVCEL
| Q4 25 | 3.90× | 0.65× | ||
| Q3 25 | 0.76× | 4.35× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 5.02× | 1.12× | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFG
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
